Caption Management’s Viking Therapeutics VKTX Stock Holding History

Caption Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,880	Closed	-$1.19M	–	2100
2025 Q4	$1.3M	Sell	36,880 -70,920	-66%	-$2.51M	0.01%	967
2025 Q3	$2.83M	Buy	+107,800	New	+$3.22M	0.02%	704
2025 Q2	–	Sell	-25,000	Closed	-$658K	–	1932
2025 Q1	$604K	Hold	25,000	–	–	0.01%	1055
2024 Q4	$1.01M	Sell	25,000 -24,500	-49%	-$1.4M	0.01%	913
2024 Q3	$3.13M	Sell	49,500 -4,400	-8%	-$258K	0.05%	433
2024 Q2	$2.86M	Buy	53,900 +14,853	+38%	+$974K	0.04%	403
2024 Q1	$3.2M	Buy	39,047 +37,543	+2,496%	+$1.67M	0.05%	414
2023 Q4	$28K	Sell	1,504 -10,416	-87%	-$136K	﹤0.01%	1249
2023 Q3	$132K	Buy	+11,920	New	+$170K	﹤0.01%	1133
2019 Q4	–	Sell	-45,000	Closed	-$328K	–	1015
2019 Q3	$309K	Buy	+45,000	New	+$334K	0.02%	548
2019 Q2	–	Sell	-30,000	Closed	-$299K	–	839
2019 Q1	$299K	Buy	+30,000	New	+$251K	0.02%	482

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Caption Management's VKTX Position: Q1 2026 in Review

Caption Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 36,880 shares — an estimated $1.19M sold.

Caption Management first reported a position in VKTX in Q1 2019 and held it in 11 quarters. The position peaked at $3.2M in Q1 2024. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Caption Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Caption Management sold 36,880 Viking Therapeutics shares in Q1 2026, an estimated $1.19M.
Caption Management first reported a position in Viking Therapeutics in Q1 2019 and held it in 11 quarters.
Caption Management's Viking Therapeutics position peaked at $3.2M in Q1 2024.
413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.